New drug combo and radiation for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have stage IV colorectal cancer that is MSS (microsatellite stable).
- You have already tried at least two standard chemotherapy treatments, and they didn't work or caused too many side effects.
- You are in good general health (able to do daily activities without help).
- You have not received immunotherapy (like PD-1 or CTLA-4 inhibitors) before.
- You do not have an active autoimmune disease (like Crohn's, rheumatoid arthritis, or lupus).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of an immunotherapy drug, a targeted therapy, and a type of low-dose radiation before standard third-line treatment in patients with colorectal cancer that has spread to the liver. The goal is to see if this approach is safe and helps shrink tumors or slow cancer growth.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
This trial tests a new drug combo (fruquintinib and sintilimab) with or without radiation for people with colorectal cancer that has spread to the liver and has not responded to earlier treatments.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
This trial tests a new combination of two drugs (DSP107 and atezolizumab) compared to another drug (fruquintinib) for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to find a more effective treatment option.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.